Neoadjuvant Sacituzumab Tirumotecan with Two Immunotherapies for Cervical Cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a combination of two immunotherapy drugs and a targeted antibody-drug before standard treatment for locally advanced cervical cancer. The goal is to see if this triple therapy can shrink tumors more effectively before surgery or radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of cervical cancer called squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma (not small cell, neuroendocrine, or sarcoma).
- Your cancer is locally advanced (stage IB3, IIA2, IIB, or IIIC1r) and at least 4 cm in size.
- You have not received any other cancer treatment before this study.
- You are between 18 and 65 years old and healthy enough for daily activities (ECOG score 0 or 1).
- Your blood counts, liver and kidney function are within acceptable ranges (tested by blood work).
- You are willing to provide a tumor sample (from a past biopsy or a new one).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (sacituzumab tirumotecan and pembrolizumab) as a first maintenance treatment for cervical cancer that has spread or come back. It is for people who haven't had other cancer treatments for this stage and whose tumors have a certain protein marker (PD-L1).
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy before surgery for cervical cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemoradiation can help people with cervical cancer that has returned or spread to a few new places. The goal is to see if this combination improves outcomes for those whose cancer is no longer responding to initial treatment.
This trial tests a combination of two drugs, sacituzumab tirumotecan and tagitanlimab, for people with advanced esophageal or stomach cancer that has worsened after initial treatment. The goal is to see if this combination can help control the cancer.
This trial tests two immune-boosting drugs (iparomlimab and tuvonralimab) combined with standard chemotherapy given before surgery for locally advanced cervical cancer. The goal is to shrink the cancer and improve survival chances.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) combined with chemotherapy before surgery for locally advanced cervical cancer. It aims to shrink tumors and improve outcomes for patients who haven't had prior systemic treatment.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.